News summary

[Hengrui Medicinegaplus: Fluzopali Capsules have been approved for listing for new indications] Securities Times e Company NewsgaplusHengrui Pharmaceutical (600276) announced on the evening of May 21 that the company received the approval of the State Food and Drug Administration for the issuance of the "Drug Registration Certificate" for fluzopali capsules, approving the new Class 1 drugs and PARP inhibitors developed by the company.gaplus.gaplus..

Newsletter text

[Hengrui Pharmaceutical: Fluzopali Capsules have been approved for new indications] Securities Times e Company News, Hengrui Pharmaceutical (600276) announced on the evening of May 21 that the company received approval from the State Food and Drug Administration for the issuance of Fluzopali Capsules. The "Drug Registration Certificate" approved the launch of a new class 1 new drug developed by the company, the PARP inhibitor Fluzopali Capsules for new indications. This is the third indication for which Fluzopali has been approved for marketing.